← Back to Clinical Trials
Recruiting NCT04993859

NCT04993859 Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04993859
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition Survivors of Childhood Cancer
Study Type OBSERVATIONAL
Enrollment 152 participants
Start Date 2021-06-02
Primary Completion 2026-07-09

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 13 Years
Study Type OBSERVATIONAL
Interventions
Non-invasive Urodynamic Test (niUDS)Urinary proteomic screenDysfunctional Voiding Symptom Score Survey (DVSS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 152 participants in total. It began in 2021-06-02 with a primary completion date of 2026-07-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.

Eligibility Criteria

Inclusion Criteria: * Children aged 5-13 years old * A history of cancer * Treatment with a chemotherapy regimen including VCR and/or DOX * Completion of chemotherapy at least one year prior to study enrollment and survey completion. Exclusion Criteria: * Patients with a: * Primary pelvic tumor * Pelvic irradiation * Pre-existing bladder/bowel dysfunction * Spinal defects * Neurologic disorder * Neuro-oncologic tumor or brain metastasis * Cyclophosphamide or ifosfamide therapy

Contact & Investigator

Central Contact

Gemma Beltran

✉ gemma.beltran@childrenscolorado.org

📞 (720) 777-4418

Principal Investigator

Nicholas Cost, MD

PRINCIPAL INVESTIGATOR

Children's Hospital Colorado

Frequently Asked Questions

Who can join the NCT04993859 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 13 Years, studying Survivors of Childhood Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04993859 currently recruiting?

Yes, NCT04993859 is actively recruiting participants. Contact the research team at gemma.beltran@childrenscolorado.org for enrollment information.

Where is the NCT04993859 trial being conducted?

This trial is being conducted at Aurora, United States.

Who is sponsoring the NCT04993859 clinical trial?

NCT04993859 is sponsored by University of Colorado, Denver. The principal investigator is Nicholas Cost, MD at Children's Hospital Colorado. The trial plans to enroll 152 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology